Peritoneal Carcinomatosis Diagnosis and Treatment in China: Focusing on Training and Collaboration
Cancer has become the number one killer. The most difficult part of cancer treatment is the treatment of metastasis, particularly the peritoneal metastasis, generally referred to as peritoneal carcinomatosis (PC). Internationally, the integrated treatment strategy of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) has been developed to be the standard treatment for PC. Although the development in this field has been relatively slow, as a result of the hard work put in over the last 20 years, there has been outstanding progress and gratifying achievements in both the diagnosis and treatment of PC in China. Our center (Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University) focuses on the research in diagnostic methods for PC, CRS+HIPEC, and management of perioperative adverse events. Based on these, “Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies” is developed. Our center that is the pioneering center for this treatment in China has accumulated a wealth of experiences and achievements with more than 1000 cases of CRS+HIPEC. Additionally, our center establishes a nationwide professional training program to promote and standardize the practice of CRS+HIPEC gradually.
KeywordsPeritoneal carcinomatosis History of research Experiences and achievements Professional training
This study was supported by the Beijing Municipal Administration of Hospitals’ Ascent Plan (DFL20180701), Special Fund for the Capital Characteristic Clinical Medicine Development Project (Z161100000516077), Beijing Municipal Grant for Medical Talents Group on Peritoneal Surface Oncology (2017400003235J007), Key Discipline Development Fund of Beijing Shijitan Hospital affiliated to the Capital Medical University (2016fmzlwk), and Beijing Natural Science Foundation (7172108).
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
For this type of study, formal consent is not required.
Informed consent was obtained from all individual participants included in the study.
- 1.Li Y (2012) My views on peritoneal carcinomatosis research. Chin J Clin Oncol 39(22):1685–1686Google Scholar
- 2.Chen JQ, Wang SB, Xu HM et al (2001) Curative effect of radical gastrectomy combined with peritoneal lavage with thermal hypoosmotic solution in treatment of gastric cancer. Nat Med J China 81(12):730–732Google Scholar
- 3.Liang H, Wang P, Wang XN et al (2003) Prospective randomized trial of prophylaxis of postoperative peritoneal carcinomatosis of advanced gastric cancer: intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles. Chin J Surg 41(4):274–277Google Scholar
- 4.Zhu ZG, Tang R, Yan M et al (2006) Clinical effect of intraoperative peritoneal hyperthermic chemotherapy for advanced gastric cancer. Chin J Gastrointes Surg 9(1):26–30Google Scholar
- 6.Mei LJ, Wang LW, Zhou YF et al (2012) Role of contrast-enhanced multi-detector row computed tomography and multiplanar reconstruction in diagnosing peritoneal carcinomatosis. Chin J Clin Oncol 39(22):1745–1749Google Scholar
- 12.Peng KW, Zhang Q, Liu JY et al (2017) Venous thromboembolism prevention for peritoneal carcinomatosis patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Chin J Clin Oncol 44(8):384–389Google Scholar
- 13.Liu G, Li XB, Ji ZH et al (2018) Diagnostic value of combined detection of D-dimer and thrombin time for exclusion of lower extremity deep vein thrombosis in patients with peritoneal carcinomatosis. Chin J Gen Surg 27(6):740–746Google Scholar
- 14.Zhang YB, Ji ZH, Liu G et al (2017) A double-catheter washing and aspiration system for the treatment of gastrointestinocutaneous fistula after peritoneal cancer resection. Chin J Gen Surg 6(32):505–508Google Scholar